WO2020215266A1 - Recombinant protein for preventing swine fever virus infection and composition and cell containing the same - Google Patents
Recombinant protein for preventing swine fever virus infection and composition and cell containing the same Download PDFInfo
- Publication number
- WO2020215266A1 WO2020215266A1 PCT/CN2019/084194 CN2019084194W WO2020215266A1 WO 2020215266 A1 WO2020215266 A1 WO 2020215266A1 CN 2019084194 W CN2019084194 W CN 2019084194W WO 2020215266 A1 WO2020215266 A1 WO 2020215266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant protein
- seq
- protein
- composition
- expression cassette
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 60
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 60
- 241000710777 Classical swine fever virus Species 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000009385 viral infection Effects 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 44
- 108091033319 polynucleotide Proteins 0.000 claims description 32
- 102000040430 polynucleotide Human genes 0.000 claims description 32
- 239000002157 polynucleotide Substances 0.000 claims description 32
- 239000013604 expression vector Substances 0.000 claims description 23
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 11
- 241000590002 Helicobacter pylori Species 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229940037467 helicobacter pylori Drugs 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 102000008857 Ferritin Human genes 0.000 claims description 3
- 108050000784 Ferritin Proteins 0.000 claims description 3
- 238000008416 Ferritin Methods 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229920006318 anionic polymer Polymers 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- 108020001775 protein parts Proteins 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 20
- 241000282898 Sus scrofa Species 0.000 abstract description 15
- 206010037660 Pyrexia Diseases 0.000 abstract description 10
- 101710125507 Integrase/recombinase Proteins 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000028993 immune response Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 15
- 241000700605 Viruses Species 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 4
- 229940097277 hygromycin b Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102000008482 12E7 Antigen Human genes 0.000 description 3
- 108010020567 12E7 Antigen Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 208000001726 Classical Swine Fever Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present disclosure relates to a composition for preventing swine fever virus infection, especially a subunit vaccine for preventing swine fever virus infection.
- Classical swine fever also known as classical swine fever, is a contagious disease caused by swine fever virus. It has the characteristics of high infectivity and high mortality, which will cause a large number of pig deaths and cause serious losses in the pig industry. .
- the current swine fever vaccines can be divided into three categories.
- Traditional Lapinized Swine Fever Vaccine This vaccine is manufactured by inoculating the weakened swine fever seed virus into rabbits, collecting organs at a specific time point, grinding, filtering and freeze-drying to make lapinized pigs Plague vaccine.
- Tissue culture live virus vaccine use weakened swine fever virus to infect pig kidney cells that are not contaminated by type 1 porcine circovirus. After virus propagation, virus liquid collection, filtration and freeze drying, tissue culture live virus vaccine is obtained. 3.
- Subunit vaccines The currently commercially available subunit vaccines such as Bayovac CSF-E2 Vaccine are produced by an insect baculovirus expression system, which is to infect insect cells with a virus carrying the E2 gene to secrete recombinant E2 protein Expression, and then recombinant E2 protein to prepare vaccine.
- One purpose of the present disclosure is to provide a novel recombinant protein and a composition containing the same, which can induce an immune protective response and achieve the purpose of preventing swine fever virus infection.
- Another objective of the present disclosure is to provide an expression cassette, an expression vector containing the same, and mammalian cells carrying these expression cassettes or expression vectors, which can be used to express the recombinant protein of the present disclosure.
- the present disclosure provides a recombinant protein, which comprises: an antigen part, the amino acid sequence of which is SEQ ID NO: 01; and a ferritin part.
- the present disclosure also provides a composition for preventing swine fever virus infection, which comprises: the recombinant protein of the present disclosure and a pharmaceutically acceptable carrier.
- the present disclosure further provides an expression cassette, which comprises: an expression element including a promoter; and a first polynucleotide and a second polynucleotide operably linked to the expression element;
- the encoding of the first polynucleotide is SEQ ID NO: 01
- the encoding of the second polynucleotide is an iron-carrying protein.
- the present disclosure also provides an expression vector, which includes the expression cassette of the present disclosure.
- the present disclosure also provides a mammalian cell with the expression cassette of the present disclosure.
- the present disclosure further provides a method for expressing the recombinant protein of the present disclosure, which comprises: expressing the expression cassette of the present disclosure in a host cell.
- Figure 1 is a schematic diagram of the expression vector of Experiment 1.
- Tag DNA includes C-myc tag, Strep-tag II, and His tag.
- Figure 2 is a protein electrophoresis diagram of Experiment 1, which shows the secretion and expression of recombinant proteins of C5-1, C5-4, and C5-7 cell lines. The arrow points to the recombinant protein disclosed.
- M is a commercially available product BenchMark TM Protein Ladder (Thermo Fisher Scientific).
- Fig. 3 is a protein electrophoresis diagram of Experiment 2, which shows the secretion and expression of recombinant proteins of the C5-1 cell line on 3, 4, 6, 8, 9, 10, and 11 days. The arrow points to the recombinant protein disclosed.
- M is a commercially available product BenchMark TM Protein Ladder (Thermo Fisher Scientific).
- Fig. 4 is a protein electrophoresis diagram of Experiment 2, which shows the monomers and multimers of the recombinant protein disclosed in the present disclosure. The arrow points to the recombinant protein disclosed.
- M is a commercially available product BenchMark TM Protein Ladder (Thermo Fisher Scientific). DTT: Dithiothreitol. +: treated with DTT; -: treated without DTT.
- FIG. 5 is the analysis result of the dynamic light scattering instrument in Experiment 2, which shows that the recombinant protein of the present disclosure forms nanoparticles.
- FIG. 6 is a transmission electron microscope image of Experiment 2, which shows that the recombinant protein of the present disclosure forms nanoparticles. Left image: scale bar 100nm; right image: scale bar 20nm.
- Figure 7 shows the anti-swine fever virus antibody titer of the pig serum in experiment three.
- Figure 8 shows the survival rate of experimental pigs in Experiment 3 after swine fever virus challenge.
- encode/encoding refers to the process by which the polynucleotide is transcribed and/or translated to produce a polypeptide, or further form a protein.
- the "first polynucleotide encoding SEQ ID NO: 01” means that the first polynucleotide is transcribed and/or translated to produce a protein, and its sequence is SEQ ID NO: 01.
- the "second polynucleotide encoded as an iron-carrying protein” means that the second polynucleotide is transcribed and/or translated to produce a protein; the protein is an iron-carrying protein. Other similar narratives in this article can be interpreted based on this concept.
- the encoding can be performed in vivo or in vitro.
- the encoding can be performed in homologous cells or heterologous cells.
- prevention of swine fever virus infection refers to the prevention of illness or symdrome caused by swine fever virus infection. Specifically, for example, preventing the occurrence of discomfort or symptoms caused by swine fever virus, or reducing the degree of discomfort or symptoms. Those skilled in the art should understand that the "prevention of swine fever virus infection” does not mean that the designated individual is completely free from swine fever virus infection, but from the viewpoint of epidemic prevention, the harm of swine fever virus to the designated individual is reduced .
- sequence is SEQ ID NO or similar descriptions as used herein means that the referred protein or polynucleotide contains the referred sequence, but is not limited to the referred sequence.
- the "antigen portion whose amino acid sequence is SEQ ID NO: 01" as described herein means that the amino acid sequence of the antigen portion includes SEQ ID NO: 01 (in a specific embodiment, it is mainly composed of SEQ ID NO: 01). :01), but those skilled in the art can modify the referred sequence based on general knowledge in the field according to their needs, so that the modified sequence includes sequences other than SEQ ID NO: 01.
- the present disclosure does not exclude the N-terminal or C-terminal extension of the protein of the present disclosure by 1 to several amino acids.
- the present disclosure does not exclude the extension of sequences of other proteins at the N-terminus or C-terminus of the protein of the present disclosure based on specific usage requirements.
- various affinity tags such as His tag, Strep tag and T7 tag can be bound to the N-terminus or C-terminus of SEQ ID NO: 01.
- the antibodies corresponding to these affinity tags can be used to detect the expression of recombinant protein (for example, applied to the Western blot method).
- This modified sequence should still belong to the scope of this disclosure unless it has lost the effect of this disclosure for preventing swine fever virus infection.
- operably linked means that two or more segments of polynucleotides are connected to each other by genetic engineering means, and these polynucleotides are guaranteed to be able to be used by the host (referred to herein as being used for expression).
- the nucleotide sequence of the organism) is recognized and encoded as the desired protein. Specifically, if it is necessary to fill in several nucleotides between the connected polynucleotides in actual operation, it must be ensured that the filled-in nucleotides will not cause the downstream polynucleotides to encode ⁇ Offset. For example, the full length of the sequence of the filled-in nucleotides should be a multiple of 3, because a codon should have 3 nucleotides.
- the first aspect of this disclosure is about a recombinant protein and a composition containing the same.
- the recombinant protein is a fusion protein and includes an antigenic moiety and an iron carrying protein moiety (ferritin).
- the antigen part refers to the part of the recombinant protein that mainly induces the host immune response.
- the present disclosure does not exclude that other parts of the recombinant protein also have the effect of inducing host immune response.
- the amino acid sequence of the antigen part is SEQ ID NO: 01.
- the antigen part is encoded by SEQ ID NO:03.
- the sequence used to encode the antigen portion may be changed to meet the codon usage bias of the organism. ).
- the iron-carrying protein is as defined in the art; preferably, the iron-carrying protein used in the present disclosure is partially derived from Helicobacter pylori.
- "derived from Helicobacter pylori” means that the amino acid sequence of the iron-carrying protein portion is substantially the same as the amino acid sequence of the iron-carrying protein carried by wild-type Helicobacter pylori. This description does not limit the iron-carrying protein used in this disclosure to be purified or isolated from Helicobacter pylori.
- the amino acid sequence of the iron-carrying protein portion is SEQ ID NO: 02. Feasibly, the iron-carrying protein part is encoded by SEQ ID NO:04.
- a linker is further included between the antigen portion and the iron-carrying protein portion.
- the amino acid sequence of the linker is SEQ ID NO: 05.
- the composition for preventing swine fever virus infection of the present disclosure includes: the recombinant protein of the present disclosure and a pharmaceutically acceptable carrier.
- the concentration of the recombinant protein is 1 to 60 ⁇ g/mL, which is based on the total volume of the composition: preferably, 7.5 to 30 ⁇ g/mL; more preferably, it is 7.5 to 15 ⁇ g/mL.
- the concentration of the recombinant protein is any one of the following concentrations or a concentration between any two concentrations: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59,60 ⁇ g/mL.
- the pharmaceutically acceptable carrier is water, phosphate buffered saline, alcohol, glycerol, chitin, alginate, chondroitin, vitamin E, minerals, or a combination thereof.
- the composition is adjusted to be solid, liquid, or colloidal, depending on the needs of the user.
- the composition is stored in a container (for example, a glass bottle) for the convenience of users.
- the composition further includes an adjuvant.
- the adjuvant can be, but is not limited to: Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum glue, surfactant, anionic polymer, peptide, oil emulsion or a combination thereof.
- commercially available adjuvants can be selected, for example, but not limited to: Montanide TM ISA 201 VG (SEPPIC, France).
- the ratio of the adjuvant to the recombinant protein may be determined according to the situation: feasible, the ratio is 1:1 (w/w).
- the second aspect of the present disclosure relates to an expression cassette, an expression vector containing the same, and mammalian cells with these expression cassettes or expression vectors.
- the expression cassette referred to in the present disclosure refers to a polynucleotide comprising an expression element, and a first polynucleotide and a second polynucleotide operably linked to the expression element:
- the expression element includes a promoter; the first polynucleotide encodes SEQ ID NO: 01, and the second polynucleotide encodes an iron-carrying protein.
- the second polynucleotide encodes SEQ ID NO: 02.
- the second polynucleotide is SEQ ID NO: 04.
- the recombinant protein disclosed in the present disclosure can be obtained after the expression cassette is expressed. Feasibly, the expression cassette is SEQ ID NO: 08.
- the expression vector of the present disclosure is an expression cassette with the present disclosure.
- the expression vector has a sequence that can be replicated in a predetermined host.
- the expression vector further comprises a sequence encoding a signal peptide, tag DNA, or a combination thereof.
- the expression vector is used in a mammalian cell expression system.
- the mammalian cell with the expression cassette or expression vector disclosed in the present disclosure refers to a mammalian cell, which is transfected into the cell by the cell engineering technology. Feasibly, the transfection is performed with electroporation technology.
- the expression cassette or expression vector will be maintained in the cell after being transfected into the cell. More preferably, after the expression cassette or expression vector is transfected into the cell, it will replicate as the cell replicates.
- the mammalian cell is a Chinese hamster ovary cell (CHO cell).
- the present disclosure also relates to a method for expressing the recombinant protein of the present disclosure, which comprises: expressing the expression cassette in the mammalian cell of the present disclosure.
- the expression cassette is an expression vector in the present disclosure.
- the method may further include a purification step to obtain the recombinant protein expressed by the mammalian cell.
- Experiment 1 Construction of expression vector and transfection of CHO cells.
- CHO-S cells (Thermo Fisher Scientific, USA) were used as host cells for the production of recombinant proteins.
- HyClone CDM4PERMAb culture medium (GE Healthcare, USA) was used for serum-free suspension culture of CHO cells, and additional Penicillin-Streptomycin (Penicillin-Streptomycin, Thermo Fisher Scientific; Penicillin final concentration was 100U/mL, Streptomycin final concentration 100 ⁇ g/mL) and GlutaMAX TM Supplement (Thermo Fisher Scientific; final concentration is 6mM).
- the semi-solid medium used to screen stable cell lines is ClonaCell TM -CHO ACF methylcellulose-based semi-solid medium (STEMCELL Technologies, USA), and additional hygromycin B (Hygromycin B, Thermo Fisher Scientific; final The concentration is 400 ⁇ g/mL).
- additional cell culture additives HyClone Cell Boost Kit, GE Healthcare may be added depending on the situation.
- polynucleotide (SEQ ID NO:07) that can encode the recombinant protein disclosed in the present disclosure according to the preferred codons of CHO cells.
- the polynucleotide may encode a fusion protein of SEQ ID NO: 06, which includes the E2 protein of classical swine fever virus and the iron-carrying protein derived from Helicobacter pylori.
- Table 1 The amino acid sequence of the fusion protein prepared in Experiment 1.
- the polynucleotide is embedded in a mammalian cell expression vector.
- the expression vector used in this experiment still carries an enhancer-promoter from the immediately-early gene of human cytomegalovirus (CMV). promoter, sequence encoding mouse IgK secretory signal (immunoglobulin kappa secretory signal), and tag DNA (please refer to Figure 1).
- DNA transfection was performed using Amaxa TM Cell Line Nucleofector TM Kit V (Lonza Bioscience, USA) transfection reagent and Nucleofector 2b Device electroporation cell transfection instrument.
- the number of CHO cells during transfection was 2 ⁇ 10 6 , and the dosage of expression vector was 1 ⁇ g.
- hygromycin B was added to select drug-resistant cell lines.
- the mini-pool selected by hygromycin B was cultured in ClonaCell TM -CHO ACF semi-solid medium at a concentration of about 600 cells/mL.
- ClonaCell TM -CHO ACF semi-solid medium at a concentration of about 600 cells/mL.
- clump about 7 to 9 days
- use the ClonePix FL instrument to select candidate cell lines to culture in a 96-well plate.
- the cells grow to nearly full coverage move the cells to a 48-well plate and continue to culture for two days.
- 100 ⁇ L of the cell culture supernatant was taken for sandwich enzyme-linked immunosorbent assay (ELISA) analysis to screen cell populations that can highly express the recombinant protein disclosed herein.
- ELISA sandwich enzyme-linked immunosorbent assay
- the capture antibody used in the ELISA method is a rabbit anti-His antibody (Rabbit anti-6-His Antibody, Bethyl Laboratories, USA); the detection antibody is a rabbit anti-c-myc antibody (Rabbit). anti-c-myc Antibody HRP Conjugated, Bethyl Laboratories, USA); the coloring agent used is TMB substrate solution (United States Biological, USA). Measure the absorbance of each well with an ELISA reader at 450nm. From the ELISA results, cell lines with high antigen expression were screened out.
- the replenishing antibody used in ELISA specific to E2 protein is WH303 monoclonal antibody (APHA, UK); the labeled detection antibody is rabbit anti-c-myc antibody; the coloring agent used is TMB substrate solution. Measure the absorbance of each well with an ELISA reader at 450nm. Based on the results of ELISA and protein electrophoresis, cell lines with high antigen expression were screened out.
- the selected cell lines were cultured in ClonaCell TM -CHO ACF semi-solid medium, and the above-mentioned screening steps were repeated 5 times.
- the high antigen-expressing cell strains obtained after screening were mixed with CELLBANKER 2 (Nippon Zenyaku Kogyo, Japan) serum-free cell freezing solution and then frozen.
- the experimental results are shown in Figure 2.
- the C5-1 cell line has the best expression and the cell growth is stable. Therefore, in this experiment, the C5-1 cell line was selected as the seed cell for subsequent production of the recombinant protein disclosed herein, and the seed cell bank was established with it.
- CHO cells from the seed cell bank were used for shaking flask culture with 5L medium. After culturing for 11 days, the cell culture solution was centrifuged at 20,000 ⁇ g for 2 hours and the supernatant was collected. The supernatant was filtered with a 0.22 ⁇ m filter membrane.
- Recombinant protein was purified using immobilized metal ion affinity resin Ni Sepharose excel (GE Healthcare, Sweden). The dynamic light scattering instrument ZetaSizer ZEN 3600 (Malvern, USA) and the transmission electron microscope JEM-2100F (JEOL, Japan) were used to analyze the ability of recombinant proteins to form nanoparticles.
- Protein electrophoresis results showed that the C5-1 cell line can stably secrete and express recombinant proteins (Figure 3).
- extracellular recombinant proteins can be purified using immobilized metal ion affinity resin.
- the purified recombinant protein is treated with dithiothreitol (DTT), which can break the disulfide bond between protein molecules.
- DTT dithiothreitol
- the molecular weight of the monomer protein is about 70kDa; without DTT treatment, the purified recombinant protein will have intermolecular interactions.
- Form multimers Figure 4).
- the recombinant protein solution purified in experiment two was adjusted to a specific concentration and mixed with Montanide TM ISA 201VG adjuvant (SEPPIC, France) at a ratio of 1:1 (w/w) to prepare V-1311, V-1331, There are 5 vaccines, V-1332, V-1333 and V-1334 (Table 2).
- normal saline containing 0.01% Thiomersal (w/v) was mixed with ISA 201 VG adjuvant to prepare a control group V-1335 without antigen. Store the vaccine in a refrigerator at 4°C for later use.
- GMO genetically modified organism
- the number of pigs in each group is 2 to 4; groups A to E are experimental groups, and group F is a control group.
- Pigs were immunized by intramuscular injection once at 9 weeks of age, with a dose of 2 mL.
- the pig test groups are as follows in Table 2.
- Anti-swine fever virus antibodies can be seen to rise in the sera collected three weeks after immunization (12 weeks old) of pigs administered the composition of the present disclosure; among them, the immunization amount of E2 antigen is 60, 30 and 15 ⁇ g The results of the /dose group were better ( Figure 7).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
组别Group | 猪只数量Number of pigs | 本实验组合物Composition of this experiment | E2抗原量(μg)/剂(2mL)E2 antigen amount (μg)/dose (2mL) |
AA | 22 | V-1311V-1311 | 6060 |
BB | 44 | V-1331V-1331 | 3030 |
CC | 44 | V-1332V-1332 | 1515 |
DD | 44 | V-1333V-1333 | 7.57.5 |
EE | 33 | V-1334V-1334 | 3.753.75 |
FF | 33 | V-1335V-1335 | 00 |
Claims (29)
- 一种重组蛋白质,其包含:A recombinant protein comprising:抗原部分,其氨基酸序列为SEQ ID NO:01;及The antigen part, whose amino acid sequence is SEQ ID NO: 01; and携铁蛋白质(ferritin)部分。Iron carrying protein (ferritin) part.
- 如权利要求1的重组蛋白质,其中所述抗原部分是由SEQ ID NO:03所编码。The recombinant protein of claim 1, wherein the antigen portion is encoded by SEQ ID NO:03.
- 如权利要求1的重组蛋白质,其中所述携铁蛋白质部分是源自幽门螺杆菌。The recombinant protein of claim 1, wherein the iron-carrying protein portion is derived from Helicobacter pylori.
- 如权利要求1的重组蛋白质,其中所述携铁蛋白质部分的氨基酸序列为SEQ ID NO:02。The recombinant protein of claim 1, wherein the amino acid sequence of the iron-carrying protein portion is SEQ ID NO: 02.
- 如权利要求4的重组蛋白质,其中所述携铁蛋白质部分是由SEQ ID NO:04所编码。The recombinant protein of claim 4, wherein the iron-carrying protein portion is encoded by SEQ ID NO:04.
- 如权利要求1的重组蛋白质,其包含连结子以连结所述抗原部分及非血基铁质蛋白质部分;其中所述连结子的氨基酸序列为SEQ ID NO:05。The recombinant protein according to claim 1, which comprises a linker to link the antigen part and the non-hematinous protein part; wherein the amino acid sequence of the linker is SEQ ID NO: 05.
- 如权利要求1的重组蛋白质,其中所述重组蛋白质的氨基酸序列为SEQ ID NO:06。The recombinant protein of claim 1, wherein the amino acid sequence of the recombinant protein is SEQ ID NO: 06.
- 如权利要求1的重组蛋白质,其是由SEQ ID NO:07所编码。The recombinant protein of claim 1, which is encoded by SEQ ID NO:07.
- 一种用于预防猪瘟病毒感染的组合物,其包含:如权利要求1至8中任一项所述的重组蛋白质及医药可接受的载剂。A composition for preventing swine fever virus infection, comprising: the recombinant protein according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier.
- 如权利要求9的组合物,其中所述重组蛋白质的浓度为1至60μg/mL,其是以所述组合物的总体积为基础。The composition of claim 9, wherein the concentration of the recombinant protein is 1 to 60 μg/mL, which is based on the total volume of the composition.
- 如权利要求10的组合物,其中所述重组蛋白质的浓度为7.5至30μg/mL,其是以所述组合物的总体积为基础。The composition of claim 10, wherein the concentration of the recombinant protein is 7.5 to 30 μg/mL, which is based on the total volume of the composition.
- 如权利要求10的组合物,其中所述重组蛋白质的浓度为7.5至15μg/mL,其是以所述组合物的总体积为基础。The composition of claim 10, wherein the concentration of the recombinant protein is 7.5 to 15 μg/mL, which is based on the total volume of the composition.
- 如权利要求9的组合物,其进一步包含佐剂。The composition of claim 9, which further comprises an adjuvant.
- 如权利要求13的组合物,其中所述佐剂包含:弗氏完全佐剂、弗氏不完全佐剂、铝胶、表面活性剂、阴离子型聚合物、肽、油乳液或其组合。The composition according to claim 13, wherein the adjuvant comprises: Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum glue, surfactant, anionic polymer, peptide, oil emulsion or a combination thereof.
- 如权利要求9的组合物,其中所述医药可接受的载剂为水、磷酸缓冲食盐水、醇、甘油、甲壳素、海藻酸盐、软骨素、维生素E、矿物质、或其组合。The composition of claim 9, wherein the pharmaceutically acceptable carrier is water, phosphate buffered saline, alcohol, glycerin, chitin, alginate, chondroitin, vitamin E, minerals, or a combination thereof.
- 一种表达卡匣,其包含:An expression cassette, which comprises:表达元件,其包含启动子;及An expression element, which includes a promoter; and与所述表达元件可操作性地连接的第一聚核苷酸及第二聚核苷酸;所述第一聚核苷酸编码为SEQ ID NO:01,且所述第二聚核苷酸编码为携铁蛋白质。A first polynucleotide and a second polynucleotide operably linked to the expression element; the first polynucleotide encodes SEQ ID NO: 01, and the second polynucleotide Encoded as iron carrying protein.
- 如权利要求16的表达卡匣,其中所述第二聚核苷酸编码为SEQ ID NO:02。The expression cassette of claim 16, wherein the second polynucleotide encodes SEQ ID NO: 02.
- 如权利要求16的表达卡匣,其中所述第一聚核苷酸为SEQ ID NO:03,其中所述第二聚核苷酸为SEQ ID NO:04。The expression cassette of claim 16, wherein the first polynucleotide is SEQ ID NO: 03, and the second polynucleotide is SEQ ID NO: 04.
- 如权利要求16的表达卡匣,其表达如权利要求1至8中任一项所述的重组蛋白质。The expression cassette according to claim 16, which expresses the recombinant protein according to any one of claims 1 to 8.
- 如权利要求19的表达卡匣,其中所述重组蛋白质的氨基酸序列为SEQ ID NO:06。The expression cassette of claim 19, wherein the amino acid sequence of the recombinant protein is SEQ ID NO: 06.
- 如权利要求16的表达卡匣,其为SEQ ID NO:08。The expression cassette of claim 16, which is SEQ ID NO: 08.
- 一种表达载体,其包含如权利要求16至21中任一项所述的表达卡匣。An expression vector comprising the expression cassette according to any one of claims 16-21.
- 如权利要求22的表达载体,其是用于哺乳动物细胞表达系统。The expression vector of claim 22, which is used in a mammalian cell expression system.
- 一种哺乳动物细胞,其带有如权利要求16至21中任一项所述的表达卡匣。A mammalian cell with the expression cassette according to any one of claims 16 to 21.
- 如权利要求24的哺乳动物细胞,其带有如权利要求22至23中任一项所述的表达载体。The mammalian cell according to claim 24, which carries the expression vector according to any one of claims 22 to 23.
- 如权利要求24的哺乳动物细胞,其为中国仓鼠卵巢细胞。The mammalian cell of claim 24, which is a Chinese hamster ovary cell.
- 一种表达如权利要求1至8中任一项所述的重组蛋白质的方法,其包含:于宿主细胞中表达如权利要求16至21中任一项所述的表达卡匣。A method for expressing the recombinant protein according to any one of claims 1 to 8, comprising: expressing the expression cassette according to any one of claims 16 to 21 in a host cell.
- 如权利要求27的方法,其中所述宿主细胞是如权利要求24至26中任一项所述的哺乳动物细胞。The method according to claim 27, wherein the host cell is a mammalian cell according to any one of claims 24 to 26.
- 如权利要求27的方法,其中于表达所述表达卡匣后,进一步包含纯化所述重组蛋白质的过程。The method of claim 27, wherein after expressing the expression cassette, it further comprises a process of purifying the recombinant protein.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/084194 WO2020215266A1 (en) | 2019-04-25 | 2019-04-25 | Recombinant protein for preventing swine fever virus infection and composition and cell containing the same |
JP2021562905A JP7391997B2 (en) | 2019-04-25 | 2019-04-25 | Recombinant proteins, compositions and cells containing the same for preventing swine fever virus infection |
KR1020217035663A KR20210149121A (en) | 2019-04-25 | 2019-04-25 | Recombinant protein for preventing swine fever virus infection and composition and cell containing same |
CN201980095762.5A CN113728011A (en) | 2019-04-25 | 2019-04-25 | Recombinant protein for preventing hog cholera virus infection and composition and cell containing recombinant protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/084194 WO2020215266A1 (en) | 2019-04-25 | 2019-04-25 | Recombinant protein for preventing swine fever virus infection and composition and cell containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020215266A1 true WO2020215266A1 (en) | 2020-10-29 |
Family
ID=72941248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/084194 WO2020215266A1 (en) | 2019-04-25 | 2019-04-25 | Recombinant protein for preventing swine fever virus infection and composition and cell containing the same |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7391997B2 (en) |
KR (1) | KR20210149121A (en) |
CN (1) | CN113728011A (en) |
WO (1) | WO2020215266A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659187A (en) * | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | Ferritin fusion proteins for use in vaccines and other applications |
WO2007098717A2 (en) * | 2006-02-28 | 2007-09-07 | Centro De Ingeniería Genética Y Biotecnología | Chimeric vaccine antigens against classical swine fever virus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755087B (en) * | 2016-09-09 | 2019-02-26 | 北京博尔柯生物科技有限公司 | Stablize the expression recombinant cell lines of CSFV E 2 protein, preparation method, using and swine fever virus subunit vaccine |
-
2019
- 2019-04-25 WO PCT/CN2019/084194 patent/WO2020215266A1/en active Application Filing
- 2019-04-25 JP JP2021562905A patent/JP7391997B2/en active Active
- 2019-04-25 KR KR1020217035663A patent/KR20210149121A/en unknown
- 2019-04-25 CN CN201980095762.5A patent/CN113728011A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1659187A (en) * | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | Ferritin fusion proteins for use in vaccines and other applications |
WO2007098717A2 (en) * | 2006-02-28 | 2007-09-07 | Centro De Ingeniería Genética Y Biotecnología | Chimeric vaccine antigens against classical swine fever virus |
Non-Patent Citations (1)
Title |
---|
PAN, C. H., ET AL.: "polyprotein, partial [Classical swine fever virus]", GENBANK: AAS20416.1 [RETRIEVED FROM HTTPS://WWW.NCBI.NLM.NIH.GOV], 26 July 2016 (2016-07-26), XP55746517, DOI: 20191105172453Y * |
Also Published As
Publication number | Publication date |
---|---|
JP7391997B2 (en) | 2023-12-05 |
CN113728011A (en) | 2021-11-30 |
JP2022531560A (en) | 2022-07-07 |
KR20210149121A (en) | 2021-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022262142A1 (en) | Recombinant sars-cov-2 rbd tripolymer protein vaccine capable of generating broad-spectrum cross-neutralization activity, preparation method therefor, and application thereof | |
CN111671890B (en) | Novel coronavirus vaccine and application thereof | |
CN112076315A (en) | Nano antigen particle fused with new coronavirus S protein and ferritin subunit, new coronavirus vaccine, and preparation method and application thereof | |
WO2022121322A1 (en) | Recombinant subunit vaccine of novel coronavirus and application thereof | |
CN107921115B (en) | Novel baculovirus vectors and methods of use | |
TWI621627B (en) | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases | |
WO2023051850A1 (en) | Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein | |
CN111234036A (en) | African swine fever virus p72 fusion protein and preparation method and application thereof | |
WO2023138334A1 (en) | Recombinant novel coronavirus protein vaccine, and preparation method and use thereof | |
WO2023051701A1 (en) | Mrna, protein and vaccine against sars-cov-2 infection | |
JPH06502069A (en) | Vaccinia vector, vaccinia gene and its expression product | |
Sánchez et al. | Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge | |
KR20220009960A (en) | Recombinant Classical Swine Fever Virus | |
Yenkoidiok-Douti et al. | In vivo characterization of Plasmodium berghei P47 (Pbs47) as a malaria transmission-blocking vaccine target | |
CN112812193A (en) | Recombinant protein vaccine of norovirus GII.4 type and enterovirus 71 type | |
WO2023138333A1 (en) | Recombinant sars-cov-2 protein vaccine, and preparation method therefor and use thereof | |
WO2020215266A1 (en) | Recombinant protein for preventing swine fever virus infection and composition and cell containing the same | |
CN115960259B (en) | Preparation method and application of modularized assembled bi-component nano particles | |
Yang et al. | B602L-Fc fusion protein enhances the immunogenicity of the B602L protein of the African swine fever virus | |
CN103360497A (en) | Novel antitumor fusion protein vaccine, and preparation method and application thereof | |
TWI776048B (en) | Recombinant protein for preventing swine fever virus infection and composition and cell comprising the same. | |
Majidi et al. | Expression and Purification of Brucella spp. Lumazine Synthase Decameric Carrier in Fusion to Extracellular Domain of Influenza M2E Protein | |
Lacasta et al. | Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever | |
CN115960180A (en) | 2019-nCoV S protein mutant and genetically engineered mRNA and vaccine composition thereof | |
CN114717205A (en) | Coronavirus RBDdm variant and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19926614 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021562905 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217035663 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19926614 Country of ref document: EP Kind code of ref document: A1 |